BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kato Y, Nishiyama K, Nishimura A, Noda T, Okabe K, Kusakabe T, Kanda Y, Nishida M. Drug repurposing for the treatment of COVID-19. Journal of Pharmacological Sciences 2022. [DOI: 10.1016/j.jphs.2022.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Esposito R, Mirra D, Sportiello L, Spaziano G, D’agostino B. Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand? Biomedicines 2022;10:2815. [DOI: 10.3390/biomedicines10112815] [Reference Citation Analysis]
2 Mcgowan J, Borucki M, Omairi H, Varghese M, Vellani S, Chakravarty S, Fan S, Chattopadhyay S, Siddiquee M, Thissen JB, Mulakken N, Moon J, Kimbrel J, Tiwari AK, Taylor RT, Kang D, Jaing C, Chakravarti R, Chattopadhyay S. SARS-CoV-2 Monitoring in Wastewater Reveals Novel Variants and Biomarkers of Infection. Viruses 2022;14:2032. [DOI: 10.3390/v14092032] [Reference Citation Analysis]
3 Miyoshi H, Otomo M, Takahashi K. Clomipramine inhibits dynamin GTPase activity by L-α-phosphatidyl-L-serine stimulation.. [DOI: 10.1101/2022.09.09.507370] [Reference Citation Analysis]
4 Holubovska O, Babich P, Mironenko A, Milde J, Lebed Y, Stammer H, Mueller L, te Velthuis A, Margitich V, Goy A. RNA polymerase inhibitor enisamium for treatment of moderate COVID-19 patients: a randomized, placebo-controlled, multicenter, double-blind phase 3 clinical trial.. [DOI: 10.1101/2022.08.21.22279036] [Reference Citation Analysis]